Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
You may also be interested in...
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.
Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.
bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole.